Free Trial
ASX:PBP

Probiotec (PBP) Stock Price, News & Analysis

About Probiotec Stock (ASX:PBP)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
26,253 shs
Average Volume
N/A
Market Capitalization
A$242.34 million
P/E Ratio
21.99
Dividend Yield
2.43%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Probiotec and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PBP Stock News Headlines

2 Incredible Dividend Growers to Buy Hand Over Fist in March
“Sell Nvidia before earnings”
Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.tc pixel
See More Headlines

PBP Stock Analysis - Frequently Asked Questions

Probiotec Limited (ASX:PBP) posted its quarterly earnings data on Tuesday, February, 26th. The company reported $0.02 earnings per share for the quarter. Probiotec had a net margin of 5.15% and a trailing twelve-month return on equity of 13.26%.

Company Calendar

Last Earnings
2/26/2019
Today
8/27/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
ASX:PBP
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
A$0.10
Trailing P/E Ratio
21.99
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
A$8.69 million
Net Margins
5.15%
Pretax Margin
N/A
Return on Equity
13.26%
Return on Assets
5.09%

Debt

Debt-to-Equity Ratio
100.87
Current Ratio
0.81
Quick Ratio
1.04

Sales & Book Value

Annual Sales
A$221.22 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
16.79
Book Value
A$1.07 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
81,320,000
Free Float
N/A
Market Cap
A$242.34 million
Optionable
Not Optionable
Beta
0.44
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (ASX:PBP) was last updated on 8/27/2025 by MarketBeat.com Staff
From Our Partners